

Preclinical results of AdjuCor's technology to be presented at the upcoming 101st annual meeting of the American Association for Thoracic Surgery (AATS)

MUNICH, Germany, February 1st, 2021 – In another great achievement for AdjuCor's ground-breaking new technology within a short period of time, its submitted abstract has been accepted for presentation at the prestigious 101st American Association for Thoracic Surgery (#AATS2021). Prof. Stephan Schueler will be presenting specifics relating to the augmentation technology.

Professor Stephan Schueler, Head of Mechanical Circulation Support at the Newcastle upon Tyne Freeman Hospital, UK, will be presenting the latest preclinical data, taking a deep dive focus on the impact of precise electro-mechanical synchronization on haemodynamic performance.

The CEO of AdjuCor, Professor Wildhirt commented: "It goes without saying that it is a very real privilege to be invited to take the stage at this renowned conference. We are very grateful for the opportunity that Prof. Schueler will be able to share these intricacies of what is required to enable this technology to work in the clinical setting."

The organizers of the 101st annual meeting of the American Association for Thoracic Surgery have decided to hold a completely virtual event, in light of the ongoing COVID-19 pandemic. More details, including finalization of the meeting program will be announced shortly.

AdjuCor's Innovative Extravascular, Biventricular Cardiac Support Technology

What sets AdjuCor' patented technology apart from the other LVADs currently available on the market, is its unique non-blood-contacting solution, its ability to support both ventricles, and its innovative patient-specific design. It is implanted by a heart team (cardiologist and surgeon) around the heart within a few minutes on the beating heart without sutures. It completely avoids blood contact and thereby any blood-related complications including strokes and bleeding – an invaluable advantage that cannot be over-stated. The energy transferred to the heart may be adjusted to each patient's need. It thereby dramatically enhances the care of patients with heart failure and improves their quality of life.

AdjuCor was founded as GmbH in 2012 by the Cardiothoracic Surgeon Stephen Wildhirt and is funded by private investors, the European Union, as well as German and Bavarian entities. The company employs over thirty experts in all fields required and has received over 13 million euros of financing.

To find out more visit: www.adjuCor.com

Contact: pr@adjuCor.com